SEC Form 3 · accession 0001144204-18-066575

Marker Therapeutics, Inc. · MRKR

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Tsvetelina P Hoang

Officer — VP, Research and Development

Period of report

Dec 21, 2018

Accepted (ET)

Dec 28, 2018 · 4:14 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001094038

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock	holding	—	—		—	179,711	I	By Husband

Table II — derivative securities

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Employee Stock Option (Right to Buy)^F1	$9.18	holding	—	—	—	—	Oct 19, 2028	Common Stock	200,000	—	D
Employee Stock Option (Right to Buy)^F2	$9.18	holding	—	—	—	—	Oct 19, 2028	Common Stock	1,359,855	—	I

Explanation of responses

F1Represents options granted under the Company's 2014 Omnibus Stock Ownership Plan, as amended for service as the Company's Vice President, Research and Development. One quarter of the shares vest on the first anniversary of the grant date, the remainder of the shares vest in monthly installments over a three year period upon the continued employment of the Reporting Person by the Company through the vesting dates. The option exercise price is the closing price on the date of the grant, October 19, 2018.
F2Represents options granted under the Company's 2014 Omnibus Stock Ownership Plan, as amended to Peter Hoang, Dr. Hoang's husband serves as the Company's Chief Executive Officer and President. The options vested and were exercisable immediately. The option exercise price is the closing price on the date of the grant, October 19, 2018.

Remarks

* Mr. Mark A. Catchur is signing as Attorney-in-Fact pursuant to power of attorney dated December 21, 2018 granted by the Reporting Person, a copy of which is filed as an exhibit and incorporated herein by reference.